Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

Seong Yoon Yi,Young Suk Park,Hyo Song Kim,Hyun Jung Jun,Kyoung Ha Kim,Myung Hee Chang,Min Jae Park,Ji Eun Uhm,Jeeyun Lee,Se Hoon Park,Joon Oh Park,Jong Kyun Lee,Kyu Taek Lee,Ho Yeong Lim,Won Ki Kang

Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

2009

Seong Yoon Yi
Young Suk Park
Hyo Song Kim
Hyun Jung Jun
Kyoung Ha Kim
Myung Hee Chang
Min Jae Park
Ji Eun Uhm
Jeeyun Lee
Se Hoon Park
Joon Oh Park
Jong Kyun Lee
Kyu Taek Lee
Ho Yeong Lim
Won Ki Kang

Purpose The phase II study was conducted to evaluate the efficacy and safety of irinotecan as salvage single-agent chemotherapy in patients with advanced pancreatic cancer.

Keywords:

Phases of clinical research
Pancreatic disease
Biochemistry
Pancreatic cancer
Cancer
Performance status
Gemcitabine
Antimetabolite
Irinotecan
Medicine
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations